SCHEMBL1001483

SCHEMBL1001483

COC(=O)c1cccc(S(=O)(=O)c2ccccn2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 1/20 0.54
LOX P28300 1/20 0.50
KDM4E B2RXH2 6/20 0.49
ALDH1A1 P00352 3/20 0.49
KMT2A Q03164 2/20 0.49
PKM P14618 2/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
KDM6B O15054 1/20 0.47
KDM5C P41229 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
KDM2A Q9Y2K7 1/20 0.47
KDM3A Q9Y4C1 1/20 0.47
POLB P06746 2/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
ALOX15 P16050 1/20 0.45
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL994515 0.83 KDM4E (0.54) KDM4EALDH1A1PKMKDM6BKDM5C
SCHEMBL2884607 0.82 LOX (0.66) SLC40A1LOXKDM4EALDH1A1KMT2A
SCHEMBL1000940 0.79 RAB9A (0.48) KDM4EALDH1A1KMT2AHTTTSHR
SCHEMBL9008002 0.78 ALDH1A1 (0.59) SLC40A1LOXKDM4EALDH1A1KMT2A
SCHEMBL1100084 0.78 ALDH1A1 (0.59) SLC40A1LOXKDM4EALDH1A1KMT2A
SCHEMBL31511805 0.77 LOX (0.60) SLC40A1LOXKDM4EALDH1A1KMT2A
SCHEMBL16699291 0.76 LOX (0.51) SLC40A1LOXKDM4EALDH1A1KMT2A
SCHEMBL38455 0.76 ALDH1A1 (0.58) SLC40A1LOXKDM4EALDH1A1KMT2A
SCHEMBL6774989 0.76 KDM4E (0.44) KDM4EALDH1A1KMT2APKMGAA
SCHEMBL1002215 0.75 SMN1; SMN2 (0.54) KDM4EALDH1A1KMT2APOLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280001-B1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD KK (JP) 2014-10-15 EP disclosed
US-8420823-B2 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient MSD K.K. (JP) 2013-04-16 US disclosed
EP-2280001-A1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT Banyu Pharmaceutical Co., Ltd. (JP) 2011-02-02 EP disclosed
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD K.K. (JP) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT ELOVL1, ELOVL6, ELOVL3 SLC40A1 1948/4885LOX 2314/4885KDM4E 1335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.